Patent Ductus Arteriosus

Patent ductus arteriosus (PDA) is a congenital cardiovascular anomaly characterized by the persistent patency of the ductus arteriosus, a fetal vascular connection between the pulmonary artery and the descending aorta. In fetal life, the ductus arteriosus is essential for shunting blood away from the non-functional lungs and toward the systemic circulation. Normally, functional closure occurs within the first few days after birth due to smooth muscle contraction and subsequent anatomical remodeling. Failure of this closure results in a persistent left-to-right shunt, leading to volume overload of the left heart, pulmonary overcirculation, and, if left untreated, progressive cardiac remodeling, congestive heart failure, and potentially fatal complications. PDA is one of the most common congenital heart defects in dogs and is also recognized in cats, albeit less frequently. The clinical presentation varies from an asymptomatic murmur to severe heart failure, depending on the size of the shunt and the age at diagnosis.

The exact etiology of PDA is not fully understood, but it is considered a multifactorial congenital defect with a strong genetic component. In dogs, a hereditary basis is well-established, particularly in certain breeds such as the Poodle, Pomeranian, Collie, Shetland Sheepdog, and German Shepherd. The mode of inheritance is likely polygenic, with a heritability estimate of around 0.5 in some breeds. In cats, a genetic predisposition is also suspected, but the evidence is less robust. Environmental factors during gestation, such as maternal drug exposure (e.g., prostaglandin synthetase inhibitors), maternal illness, or nutritional deficiencies, may contribute to the failure of ductal closure, but these are not well-documented in veterinary medicine. The molecular mechanisms underlying PDA involve the disruption of the normal postnatal vasoconstrictive response of the ductus arteriosus, which is mediated by oxygen tension, prostaglandins, and nitric oxide. In particular, a deficiency in the smooth muscle contractile apparatus or an imbalance in vasoactive mediators may lead to persistent patency.

PDA is one of the most frequently diagnosed congenital heart defects in dogs, accounting for approximately 20-30% of all congenital cardiac anomalies. It is less common in cats, representing about 10-15% of feline congenital heart disease. The condition is more prevalent in purebred dogs, with a higher incidence in breeds such as the Maltese, Bichon Frise, Yorkshire Terrier, and Toy Poodle. A female predisposition has been reported in some studies, with a female-to-male ratio of approximately 2:1. The age at diagnosis is typically within the first year of life, often detected during routine physical examination when a characteristic continuous murmur is auscultated. There is no significant geographic variation, but the prevalence may be higher in certain breeding lines due to genetic selection. In cats, no strong breed predisposition is noted, but the condition is occasionally seen in domestic shorthair cats. The overall incidence in the general canine population is estimated at 0.2-0.5%.

The ductus arteriosus in the fetus allows blood to bypass the non-functional lungs, shunting from the pulmonary artery to the descending aorta. After birth, the increase in arterial oxygen tension and the decrease in circulating prostaglandins trigger ductal constriction and eventual anatomical closure. When the ductus remains patent, a left-to-right shunt occurs because systemic vascular resistance is higher than pulmonary vascular resistance. This results in a continuous flow of blood from the aorta into the pulmonary artery during both systole and diastole, leading to pulmonary overcirculation. The left atrium and left ventricle receive increased venous return, causing volume overload and eccentric hypertrophy. Over time, the left ventricle dilates, and the left atrium enlarges. The chronic volume overload leads to increased left ventricular end-diastolic pressure, which can progress to left-sided congestive heart failure, characterized by pulmonary edema and respiratory distress. In some cases, if the shunt is large, pulmonary hypertension may develop, leading to a reversal of the shunt (right-to-left) and cyanosis, a condition known as Eisenmenger syndrome. However, this is rare in dogs and cats with PDA, as the ductus is usually small to moderate in size. The pathophysiology also involves neurohormonal activation, including the renin-angiotensin-aldosterone system and sympathetic nervous system, which further contribute to cardiac remodeling and fluid retention.

Predisposing factors for PDA include genetic susceptibility, breed predisposition, and female sex. Certain breeds, such as the Poodle, Pomeranian, and Collie, have a higher risk, suggesting a hereditary component. Inbreeding and line-breeding may increase the incidence. Environmental factors during pregnancy, such as maternal infections or exposure to teratogenic drugs, may also play a role, though specific triggers are not well-defined. Additionally, the failure of ductal closure is more likely in premature or low-birth-weight neonates, as the ductus is more sensitive to prostaglandins and less responsive to oxygen. However, in veterinary medicine, most cases are diagnosed in otherwise healthy puppies and kittens, with no obvious predisposing factors other than genetics.

Clinical signs of PDA vary depending on the size of the shunt and the age of the animal. In small shunts, animals may be asymptomatic, and the condition is often detected incidentally during a routine physical examination. The hallmark finding is a continuous, machinery-like murmur, best heard over the left heart base (craniodorsal to the heart) and radiating widely. The murmur is present throughout systole and diastole, with accentuation during systole. In larger shunts, clinical signs may include exercise intolerance, tachypnea, coughing, stunted growth, and signs of congestive heart failure such as dyspnea, pulmonary crackles, and cyanosis in severe cases. In the terminal stage, animals may present with collapse, syncope, or sudden death due to arrhythmias or rupture of the pulmonary artery. In right-to-left shunting PDA (Eisenmenger syndrome), clinical signs include differential cyanosis (pink forelimbs, blue hindlimbs), polycythemia, and exercise intolerance. However, this is rare in dogs and cats.

Differential diagnoses for a continuous murmur or suspected PDA include: 1) Aortic stenosis (subaortic or valvular) – typically a systolic ejection murmur, not continuous, and may have a thrill at the left heart base; 2) Pulmonic stenosis – a systolic murmur at the left heart base, but not continuous; 3) Ventricular septal defect (VSD) – a harsh holosystolic murmur at the right sternal border, but not continuous; 4) Atrioventricular valve dysplasia (mitral or tricuspid) – regurgitant murmurs, usually systolic, with associated valve abnormalities on echocardiography; 5) Tetralogy of Fallot – a complex cyanotic congenital defect with a systolic murmur and right-to-left shunt; 6) Persistent truncus arteriosus – a rare defect with a continuous murmur and cyanosis; 7) Aortopulmonary window – a rare defect with a continuous murmur, but the location and echocardiographic findings differ; 8) Coronary artery fistula – a rare cause of a continuous murmur, but the origin and course are different; 9) Peripheral arteriovenous fistula – a continuous murmur over the site of the fistula, not cardiac; 10) Anemia or fever – can cause functional murmurs, but these are usually systolic and not continuous. Definitive differentiation is achieved through echocardiography, which will show the patent ductus and characteristic Doppler flow.

The diagnostic algorithm for PDA begins with a thorough physical examination, with particular attention to cardiac auscultation. If a continuous murmur is detected, thoracic radiographs are obtained to assess cardiac size and pulmonary vasculature. Radiographic findings may include left atrial and left ventricular enlargement, pulmonary overcirculation (increased pulmonary vessel size), and possibly pulmonary edema in cases of heart failure. Echocardiography is the gold standard for diagnosis, as it allows direct visualization of the ductus arteriosus using two-dimensional imaging and color-flow Doppler. The ductus is typically seen as a vessel connecting the descending aorta to the main pulmonary artery. Doppler echocardiography demonstrates continuous turbulent flow in the pulmonary artery. In addition, echocardiography assesses the severity of left heart enlargement and ventricular function. In cases where echocardiography is not available, cardiac catheterization and angiography can be performed, but this is rarely necessary. Electrocardiography may show left atrial and left ventricular enlargement patterns, but it is not diagnostic. For asymptomatic animals with a small PDA, the diagnostic workup may be limited to echocardiography. For animals with signs of heart failure, additional tests such as blood pressure measurement, blood gas analysis, and NT-proBNP may be helpful.

Laboratory findings in PDA are often unremarkable in asymptomatic cases. In animals with congestive heart failure, hematology may show a stress leukogram, and serum biochemistry may reveal mild elevations in liver enzymes due to hepatic congestion. Blood gas analysis may show hypoxemia in cases of right-to-left shunting. NT-proBNP (N-terminal pro-brain natriuretic peptide) is a useful biomarker that is often elevated in animals with cardiac disease and heart failure, and it can help differentiate cardiac from non-cardiac causes of respiratory signs. Troponin I may be elevated in cases of myocardial damage. In right-to-left shunting PDA, polycythemia is a characteristic finding due to chronic hypoxemia. Urinalysis is typically normal. In animals with heart failure, renal function should be assessed, as reduced renal perfusion may lead to prerenal azotemia.

Thoracic radiography is a key imaging modality in the evaluation of PDA. Typical findings include: 1) Left atrial and left ventricular enlargement, which may be seen as an increased vertebral heart score (VHS) and a rounded cardiac silhouette; 2) Pulmonary overcirculation, characterized by enlarged pulmonary arteries and veins, and increased interstitial opacity; 3) In cases of left-sided congestive heart failure, a diffuse interstitial or alveolar pattern in the caudodorsal lung fields, indicating pulmonary edema. Echocardiography is the definitive imaging tool. Two-dimensional echocardiography from a left cranial view can visualize the ductus arteriosus as a vessel connecting the descending aorta to the main pulmonary artery. Color-flow Doppler demonstrates continuous turbulent flow within the pulmonary artery. Spectral Doppler can measure the velocity of the shunt, which is typically high (often >4 m/s) in left-to-right shunting. Echocardiography also quantifies left atrial and left ventricular dimensions, and assesses systolic function (e.g., fractional shortening). In cases of pulmonary hypertension, the right ventricle may be enlarged, and the shunt velocity may be lower. Advanced imaging such as computed tomography (CT) or magnetic resonance imaging (MRI) is rarely needed but may be used for surgical planning in complex cases.

Cytology and histopathology are not typically used in the diagnosis of PDA. However, if a lung biopsy is performed in cases of severe pulmonary hypertension, histopathology may show pulmonary vascular remodeling, including medial hypertrophy and intimal proliferation. In cases of heart failure, histopathology of the lungs may reveal pulmonary edema and hemosiderin-laden macrophages. In the heart, histopathology may show eccentric hypertrophy of the left ventricle and dilation of the left atrium. These findings are non-specific and not necessary for diagnosis.

The definitive treatment for PDA is surgical ligation or minimally invasive occlusion using transcatheter techniques. Surgical ligation is performed via a left lateral thoracotomy, and the ductus is ligated with suture. Transcatheter occlusion is the preferred method in many referral centers, using devices such as Amplatz Canine Duct Occluder (ACDO) or vascular coils. The choice of method depends on the size and shape of the ductus, as well as the expertise of the clinician. Medical therapy is not curative but may be used to stabilize animals with heart failure before intervention. Emergency stabilization includes oxygen supplementation, diuretics (e.g., furosemide at 2-4 mg/kg IV or IM, then 1-2 mg/kg PO q8-12h), and vasodilators (e.g., ACE inhibitors such as enalapril at 0.5 mg/kg PO q12h). In cases of right-to-left shunting PDA, surgical closure is contraindicated, and treatment focuses on managing polycythemia (e.g., phlebotomy, hydroxyurea) and avoiding dehydration. After successful closure, the prognosis is excellent, and most animals live a normal life. Post-operative care includes pain management (e.g., opioids, NSAIDs), antibiotics (e.g., cefazolin at 22 mg/kg IV q8h), and monitoring for complications such as hemorrhage, arrhythmias, or residual shunting.

The prognosis for PDA is excellent if the condition is diagnosed and treated before the onset of severe heart failure. Surgical or transcatheter closure has a high success rate, with a perioperative mortality rate of less than 5% in experienced centers. Animals with a small PDA that is left untreated may have a normal lifespan, but they are at risk for developing infective endocarditis or, rarely, pulmonary hypertension. Animals with a large PDA that is left untreated typically develop congestive heart failure within the first year of life, and the prognosis is poor without intervention. After successful closure, clinical signs resolve, and the heart size often returns to normal over several months. The long-term prognosis is excellent, with most animals living a normal lifespan. Negative prognostic indicators include the presence of congestive heart failure at the time of diagnosis, severe left heart enlargement, and concurrent congenital anomalies.

After successful closure of PDA, follow-up is essential to monitor for complications and ensure recovery. Immediately post-operatively, animals should be monitored for arrhythmias, hemorrhage, and residual shunting. A recheck examination is typically performed at 1-2 weeks, 1 month, and 3 months after the procedure. At each visit, a physical examination, including auscultation, should be performed to ensure the murmur has resolved. Echocardiography is recommended at 1-3 months post-procedure to confirm complete closure and assess cardiac remodeling. If the heart size was enlarged pre-operatively, it may take several months to normalize. Long-term follow-up is usually not required if the closure is successful, but annual physical examinations are recommended. In animals with residual shunting, repeat intervention may be necessary. In animals with right-to-left shunting PDA, long-term management includes regular monitoring of packed cell volume (PCV) and clinical signs, and phlebotomy or hydroxyurea as needed.

Pearls: 1) The continuous murmur of PDA is pathognomonic and is best heard at the left heart base, but it may be missed in small shunts; 2) Echocardiography is essential for confirming the diagnosis and assessing the size of the shunt; 3) Transcatheter occlusion is the preferred treatment in most cases, as it is less invasive and has a shorter recovery time; 4) In asymptomatic animals with a small PDA, closure is still recommended to prevent future complications such as endocarditis. Pitfalls: 1) Misdiagnosing a continuous murmur as a systolic murmur, leading to delayed treatment; 2) Failing to recognize right-to-left shunting PDA, which is a contraindication to closure; 3) Underestimating the severity of heart failure in animals with a large PDA, leading to inadequate stabilization before surgery; 4) Not monitoring for post-operative complications such as hemorrhage or arrhythmias.

Medical therapy for PDA is primarily supportive and is used in the management of congestive heart failure or in cases where surgical closure is not possible. Furosemide: 2-4 mg/kg IV or IM initially, then 1-2 mg/kg PO q8-12h, titrated to effect. Enalapril: 0.5 mg/kg PO q12h, or benazepril at 0.25-0.5 mg/kg PO q12h. Pimobendan: 0.25-0.3 mg/kg PO q12h, may be used in cases of heart failure. Spironolactone: 1-2 mg/kg PO q12h, as an adjunctive diuretic. In cases of right-to-left shunting PDA, hydroxyurea: 50 mg/kg PO q48h, or phlebotomy to maintain PCV below 65%. Antibiotics for surgical prophylaxis: cefazolin 22 mg/kg IV at induction and every 90 minutes during surgery. Analgesics: buprenorphine 0.01-0.02 mg/kg IV or IM q8-12h, or fentanyl CRI at 2-5 mcg/kg/h. NSAIDs such as carprofen 2.2 mg/kg PO q12h or meloxicam 0.1 mg/kg PO q24h may be used for post-operative pain, but caution is advised in animals with renal impairment. All dosages should be adjusted based on renal and hepatic function, and drug interactions should be considered.

The management of PDA has evolved significantly over the past few decades. Surgical ligation was the standard of care for many years, with a reported success rate of over 95% and a low complication rate. However, transcatheter occlusion using the Amplatz Canine Duct Occluder (ACDO) has become the preferred method in many referral centers due to its minimally invasive nature and high success rate. A landmark study by Saunders et al. (2014) reported a 98% success rate with ACDO, with minimal complications. Another study by Gordon et al. (2010) compared surgical ligation and transcatheter occlusion and found similar outcomes, but transcatheter occlusion was associated with shorter hospital stays and less post-operative pain. The ACVIM consensus statement on the diagnosis and treatment of canine congenital heart disease (2015) recommends closure of PDA in all animals with a left-to-right shunt, regardless of size, to prevent long-term complications. For right-to-left shunting PDA, closure is contraindicated, and management focuses on symptomatic treatment. The prognosis after successful closure is excellent, with most animals achieving a normal lifespan. Long-term follow-up studies have shown that cardiac remodeling reverses after closure, and the risk of infective endocarditis is significantly reduced.